Company
BRAINZELL
AI-native drug discovery with patient relevant brain organoids
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Stockholm, Sweden
Record updated 17 September 2026
About
At BrainZell, we specialize in generating high-throughput brain organoids derived from induced pluripotent stem cells (iPSCs). Our innovative platform closely mimics human neural biology and includes key components of the brain's immune system, an important driver of brain diseases.